Colorectal cancer screening - Health impact and cost effectiveness

被引:98
作者
Maciosek, Michael V.
Solberg, Leif I.
Coffield, Ashley B.
Edwards, Nichol M.
Goodman, Michael J.
机构
[1] Partnership Prevent, Washington, DC 20036 USA
[2] HealthPartners Res Fdn, Minneapolis, MN USA
基金
美国医疗保健研究与质量局;
关键词
D O I
10.1016/j.amepre.2006.03.009
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Colorectal cancer is the second leading cause of cancer-related death in the United States, yet recommended screenings are not delivered to most people. This assessment of colorectal cancer screening's value to the U.S. population is part of the update to a 2001 ranking of recommended clinical preventive services found in the accompanying article. This article describes the burden of disease prevented and cost-effectiveness as a result of offering patients a choice of colorectal. cancer screening tools. Methods: Methods used were designed to ensure consistent estimates across many services and are described in more detail in the companion articles. In a secondary analysis, the authors also estimated the impact of increasing offers for colorectal cancer screening above current levels among the current cross-section of adults aged 50 and older. Results: If a birth cohort of 4 million were offered screening at recommended intervals, 31,500 deaths would be prevented and 338,000 years of life would be gained over the lifetime of the birth cohort. In the current cross-section of people aged 50 and older, 18,800 deaths could be prevented each year by offering all people in this group screening at recommended intervals. Only 58% of these deaths are currently being prevented. In year 2000 dollars, the cost effectiveness of offering patients aged 50 and older a choice of colorectal cancer screening options is $11,900 per year of life gained. Conclusions: Colorectal cancer screening is a high-impact, cost-effective service used by less than half of persons aged 50 and older.
引用
收藏
页码:80 / 89
页数:10
相关论文
共 92 条
[1]  
American Cancer Society, 2005, CANC FACTS FIG 2005
[2]  
[Anonymous], 2005, EC MOD COL CANC SCRE
[3]  
Arias Elizabeth, 2002, Natl Vital Stat Rep, V51, P1
[4]  
Balluz Lina, 2004, Morbidity and Mortality Weekly Report, V53, P1
[5]   Screening for colorectal cancer: Recommendation and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, PS ;
Homer, CJ ;
Johnson, MS ;
Klein, JD ;
Lieu, TA ;
Mulrow, CD ;
Orleans, CT ;
Peipert, JF ;
Pender, NJ ;
Siu, AL ;
Teutsch, SM ;
Westhoff, C ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (02) :129-131
[6]   Reducing colorectal cancer mortality by repeated faecal occult blood test: a nested case-control study [J].
Bertario, L ;
Russo, A ;
Crosignani, P ;
Sala, P ;
Spinelli, P ;
Pizzetti, P ;
Andreola, S ;
Berrino, F .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (06) :973-977
[7]   Compliance and findings in a Swedish population screened for colorectal cancer with sigmoidoscopy [J].
Blom, J ;
Lidén, A ;
Jeppsson, B ;
Holmberg, L ;
Påhlman, L .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (08) :827-831
[8]   Effect of physician recommendation and patient adherence on rates of colorectal cancer testing [J].
Brawarsky, P ;
Brooks, DR ;
Mucci, LA ;
Wood, PA .
CANCER DETECTION AND PREVENTION, 2004, 28 (04) :260-268
[9]   Design, organization and management of a controlled population screening study for detection of colorectal neoplasia [J].
Bretthauer, N ;
Gondal, G ;
Larsen, IK ;
Carlsen, E ;
Eide, TJ ;
Grotmol, T ;
Skovlund, E ;
Tveit, KM ;
Vatn, MH ;
Hoff, G .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (05) :568-573
[10]   Screening for colorectal neoplasia with faecal occult blood testing compared with flexible sigmoidoscopy directly in a 55-56 years' old population [J].
Brevinge, H ;
Lindholm, E ;
Buntzen, S ;
Kewenter, J .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 1997, 12 (05) :291-295